Please login to the form below

Selincro

This page shows the latest Selincro news and features for those working in and with pharma, biotech and healthcare.

Biotie also has a royalty stream from Lundbeck's sales of Selincro(nalmefene), which was launched in 2013 for the treatment of alcohol dependency.

Schultz takes Lundbeck helm after leaving Novo Nordisk

Newly launched alcohol dependency drug Selincro (nalmefene) added 41m kroner to the pot.
Brintellix first antidepressant with cognition claim in Europe

The Danish company also has a long-acting version of schizophrenia drug Abilify (aripiprazole) and alcohol addiction treatment Selincro (nalmefene) to help Brintellix return its revenues to growth.
NICE backs drug to cut alcohol consumption

NHS patients in England will now have access to Selincro (nalmefene), a once a day tablet marketed by Danish firm Lundbeck. ... Selincro has demonstrated its effectiveness in clinical trials where it has helped patients cut the amount they drink by an
Lundbeck still feeling effects from Cipralex patent loss

There were also gains for Lundbeck's new schizophrenia drug Abilify Maintena (aripiprazole) - although the company did not reveal figures - and the start of contributions from alcohol dependency treatment Selincro (nalmefene)
NICE recommends Lundbeck’s alcohol dependency drug

Lundbeck has high hopes for Selincro as it tries to overcome the impact of the loss of patent protection for its top selling treatment antidepressant Cipralex/Lexapro (escitalopram oxalate). ... The importance of new products like Selincro became even

More from news
Approximately 5 fully matching, plus 13 partially matching documents found.

Pharma deals during September 2012

from 2006 for Selincro (nalmefene), a novel opioid system modulator to treat alcohol dependence. Linked to this investment, the royalty rates in countries outside Europe and the US have been reduced ... Biotie will receive additional sales milestones on

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

CHC hires first full-time account director

Newman will help manage Clark Health Communications' business in women's health and alcohol dependence, which includes the Communiqué Award-winning campaign for Lundbeck's Selincro (nalmefene).
Bayer’s Barbara Jaszewski joins Lundbeck

Jaszewski's most pressing task will be to lead the launch of Selincro (nalmefene), which was recently recommended by the European Medicines Agency (EMA) to treat alcohol dependence.
Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Add my company

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...